Marcin Stajszczyk

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 18

Top Topics

Rheumatoid Arthritis

Idiopathic Pulmonary Fibrosis

Cardiovascular Risk Factors

Replacement Therapy

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Polish archives of internal medicine

Rheumatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Felis-Giemza, Mateusz Moskal, Krzysztof Proc, Zbigniew Guzera, Marcin Stajszczyk, Karolina Palej, Kornelia Chmurzyńska, Piotr Wiland, Krzysztof Batko, Bogdan Batko
Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk. Reumatologia 61 (6) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Bogdan Batko, Slawomir Jeka, Piotr Wiland, Agnieszka Zielińska, Maria Stopińska-Polaszewska, Marcin Stajszczyk, Magdalena Kosydar-Piechna, Mary Jane Cadatal, Jose L Rivas
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance. Rheumatology and therapy (2024)
Anna Felis-Giemza, Mateusz Moskal, Krzysztof Proc, Zbigniew Guzera, Marcin Stajszczyk, Karolina Palej, Kornelia Chmurzyńska, Piotr Wiland, Krzysztof Batko, Bogdan Batko
Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk. Reumatologia 61 (6) (2024)
Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko, Maria Maślińska, Marcin Stajszczyk, Jerzy Świerkot, Piotr Wiland, Zbigniew Michał Żuber, Krzysztof Tomasiewicz
COVID-19 prophylaxis, diagnostics, and treatment in patients with rheumatic diseases. The Polish experts panel opinion. Reumatologia 62 (1) (2024)
Anna Felis-Giemza, Mateusz Moskal, Krzysztof Proc, Zbigniew Guzera, Marcin Stajszczyk, Karolina Palej, Kornelia Chmurzyńska, Piotr Wiland, Krzysztof Batko, Bogdan Batko
Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk. Reumatologia 61 (6) (2024)
Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko, Maria Maślińska, Marcin Stajszczyk, Jerzy Świerkot, Piotr Wiland, Zbigniew Michał Żuber, Krzysztof Tomasiewicz
COVID-19 prophylaxis, diagnostics, and treatment in patients with rheumatic diseases. The Polish experts panel opinion. Reumatologia 62 (1) (2024)
Marcin Stajszczyk, Brygida Kwiatkowska, Zbigniew Michał Żuber, Bogdan Batko
Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study. Polish archives of internal medicine 134 (4) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Brygida Kwiatkowska, Zbigniew Michał Żuber, Bogdan Batko
Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study. Polish archives of internal medicine 134 (4) (2024)
Bogdan Batko, Slawomir Jeka, Piotr Wiland, Agnieszka Zielińska, Maria Stopińska-Polaszewska, Marcin Stajszczyk, Magdalena Kosydar-Piechna, Mary Jane Cadatal, Jose L Rivas
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance. Rheumatology and therapy (2024)
Marcin Stajszczyk, Brygida Kwiatkowska, Zbigniew Michał Żuber, Bogdan Batko
Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study. Polish archives of internal medicine 134 (4) (2024)
Anna Felis-Giemza, Mateusz Moskal, Krzysztof Proc, Zbigniew Guzera, Marcin Stajszczyk, Karolina Palej, Kornelia Chmurzyńska, Piotr Wiland, Krzysztof Batko, Bogdan Batko
Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk. Reumatologia 61 (6) (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)
Marcin Stajszczyk, Krzysztof Batko, Zbigniew Michał Żuber, Brygida Kwiatkowska, Magdalena Krajewska-Włodarczyk, Bogdan Batko
Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38 (4) (2024)
Marcin Stajszczyk, Grażyna Świerkowska, Katarzyna Smolik, Izabela Domysławska, Karol Charkiewicz, Włodzimierz Samborski
The perspective of Polish patients with rheumatoid arthritis - treatment expectations, patient-reported outcomes, and digital literacy (the SENSE study). Reumatologia 61 (5) (2023)
Marcin Stajszczyk, Izabela Obarska, Sławomir Jeka, Bogdan Batko
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Annals of the rheumatic diseases (2023)